Venous thrombosis with indwelling central catheter in oncology;Les thromboses veineuses sur catheter central en cancerologie

Revue de Medecine Interne

Volumn 17, Issue 10, 1996, Pages 821-825

  Devie Hubert, I ^a,b   Carlier, M ^a   Pozzo Di Borgo, C ^a  

^a Laboratoire d'Hémostase   (France)

^b INSTITUT JEAN GODINOT   (France)

Author keywords

chemotherapy; indwelling central catheter; oncology; venous thrombosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAMOXIFEN; VINCRISTINE;

CANCER; HUMAN; INDWELLING CATHETER; REVIEW; VEIN THROMBOSIS; CENTRAL VENOUS CATHETERIZATION; NEOPLASM; PATHOPHYSIOLOGY; RISK FACTOR; THROMBOPHLEBITIS;

ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; HUMANS; NEOPLASMS; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0030271720     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)82685-3     Document Type: Article

References (52)

1. Andersen AJ, Krasnow SH, Boyer MW et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989:95:71-5
2. McLean Ross AH, Griffith CDM, Anderson JR, Grieve DC. Thromboembolic complications with silicone elastomer subclavian catheters. J Parent Ent Nutr 1982;6:61-3
3. Moss JF, Wagman LD, Riihimaki DU, Terz JJ. Central venous thrombosis related to the silastic Hickman-Broviac catheter in an oncologic population. J Parent Ent Nutr 1989;13:397-400
4. Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983;52:1586-9
5. Borow M, Crowley JG. Evaluation of central venous catheter thrombogenicity. Acta Anaesthesiol Scand 1985;suppl 81:59-64
6. Hoshal VL, Ause RG, Hoskins PA. Fibrin sleeve formation on indwelling subclavian central venous catheters. Arch Surg 1971;102:353-8
7. Brismar B, Härdstedt C, Jacobson S. Diagnosis of thrombosis by catheter phlebography after prolonged central venous catheterization. Ann Surg 1981;194:779-83
8. Pusineri C, Cazenave JP. Techniques for modifying artificial surfaces. In: Cazenave JP, Davies JA, Kazatchine MD, van Aken WG, eds. Blood-surface interactions. Biological principles underlying haemocompatibility with artificial materials. Amsterdam: Elsevier, 1986:209
9. Wistbacka JO, Nuutinen LS. Catheter-related complications of total parenteral nutrition (TPN): a review. Acta Anaesthesiol Scand 1985;29:84-8
10. Williams EC. Catheter-related thrombosis. Clin Cardiol 1990;13(suppl 6):34-6
11. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990;17:147-59
12. Di Costanzo J, Sastre B, Choux R, Kasparian M. Mechanism of thrombogenesis during total parenteral nutrition: role of catheter composition. J Parent Ent Nutr 1988;12:190-4
13. Ranchère JY, Tabone E, Latour JF, Coullioud D, Biron P. Modifications de surface des cathéters veineux après chimiothérapie antinéoplasique. Ann Fr Anesth Réanim 1988;7:76-80
14. Lokich JJ, Bothe A, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol 1985;3:710-7
15. Brown-Smith JK, Stoner MH, Barley ZA. Tunneled catheter thrombosis: factors related to incidence. Oncol Nurs Forum 1990;17:543-9
16. Puel V, Caudry M, Le Metayer P et al. Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 1993;72:2248-52
17. Could JR, Carloss HW, Skinner WL. Groshong catheter-associated subclavian venous thrombosis. Am J Med 1993;95:419-23
18. Durbec O, Albanese J, Brunel MF, Papazian L, Girard N, Granthil C. Tolérance du cathéterisme veineux fémoral. Ann Fr Anesth Réanim 1989;8:614-9
19. Curelaru I, Gustavsson B. Hansson AH, Linder LE, Stenqvist O, Wojciechowski J. Material thrombogenicity in central venous catheterization. II. A comparison between plain silicone elastomer, and plain polyethylene, long, antebrachial catheters. Acta Anaesthesiol Scand 1983;27:158-64
20. Curelaru I, Bylock A, Gustavsson B et al. Dynamics of thrombophlebitis in central venous catheterization via basilic and cephalic veins. Acta Chir Scand 1984;150:285-93
21. Trousseau A. Phlegmasia alba dolens. Clinique médicale de l'Hôtel-Dieu de Paris, vol 3. Paris : JB Ballière et Fils, 1865:654
22. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992;18:353-72
23. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-31
24. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31
25. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986;4:1405-17
26. Canobbio L, Fassio T, Ardizzoni A et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986;58:1032-6
27. Sun NCJ, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10-6
28. Edwards RL, Rickles FR, Moritz TE et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602
29. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy, International Society of Thrombosis and Haemostasis. Thromb Haemost 1993;70:540-2
30. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-48
31. Falanga A, Ofosu FA, Cortelazzo S et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993;85:745-50
32. Virchow R. Gesammelte abhaldungen zur wissenschaftlichen medicin. Frankfurt FRG: Meidinger Sohn, 1856:477
33. Edwards RL, Silver J, Rickles FR. Human tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993;69:205-13
34. Edgington TS. Activation of the coagulation system in association with neoplasia. J Lab Clin Med 1980:96:1-4
35. Nemerson Y, Tissue factor and hemostasis. Blood 1988;71:1-8
36. Kubota T, Andoh K, Sadakata H, Tanaka H, Kobayashi N. Tissue factor released from leukemic cells. Thromb Haemost 1991;65:59-63
37. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79
38. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975;6:127-37
39. Donati MB, Falanga A, Consonni R et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost 1990;64:11-6
40. Gordon SG, Mourad AM. The site of activation of factor X by cancer procoagulant. Blood Coag Fibrinol 1991;2:735-9
41. Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Haemost 1992;18:424-33
42. Cozzolino F, Torcia M, Miliani A et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 1988;84:240-50
43. Lazo JS. Endothelial injury caused by antineoplasic agents. Biochem Pharmacol 1986;35:1919-23
44. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981:65:677-9
45. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-8
46. Levine MN, Gent M, Hirsh J et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engt J Med 1988;318:404-7
47. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94
48. Clarke CS, Otridge BW, Carney DN. Thromboembolism: a complication of weekly chemotherapy in the treatment on non-Hodgkin's lymphoma. Cancer 1990;66:2027-30
49. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-8
50. Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 1990;89:25-8
51. Levine M, Hirsh J, Gent M et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9
52. Greidanus J, De Vries EGE, Nieweg MB, De Langen ZJ, Willemse PHB. Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis. Eur J Cancer Clin Oncol 1987;23:1653-7